Sera Prognostics
SERA2.0402.86% ( -0.060 )
Sera Prognostics (SERA)
Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and serv...
- Open
- 2.090
- High
- 2.130
- Low
- 2.010
- Prev. Close
- 2.100
- Volume
- 24.66K
- Turnover
- 50.11K
- Avg Price
- 2.032
- Bid/Ask Ratio
- --
- Amplitude
- 5.71%
- 52wk High
- 3.950
- Volume Ratio
- 0.41
- Turnover Ratio
- 0.09%
Sera Prognostics Analyst Rating
View MoreForecast & Rating
Jul 10, 2026Price forecast
$5.50169.61%
Forecast & RatingStrong buy
4analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 29 at 03:15 PM
Sera Prognostics schedules conference call, webcast for quarterly results update
- Unusual Whales · Jul 9 at 03:07 PM
PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE
- PUBT · Jul 9 at 03:07 PM
Sera Prognostics announces new PRIME subgroup analysis publication on PreTRM test-guided care
- PUBT · Jul 1 at 03:11 PM
Sera Prognostics director Mark Christopher Capone files initial beneficial ownership statement
- Tip Ranks · Jun 30 at 03:31 PM
Sera Prognostics Adds Veteran Executive to Board
- PUBT · Jun 30 at 03:06 PM
Sera Prognostics names former Myriad Genetics CEO Mark Capone to board
